We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04985825
Recruitment Status : Withdrawn (Business decision)
First Posted : August 2, 2021
Last Update Posted : September 13, 2022
ICON plc
Information provided by (Responsible Party):
Centessa Pharmaceuticals plc ( Pega-One S.A.S. )

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : August 17, 2022
Actual Study Completion Date : August 17, 2022